Symmetry Partners LLC Takes Position in Abbott Laboratories $ABT

Symmetry Partners LLC acquired a new stake in shares of Abbott Laboratories (NYSE:ABT) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 2,015 shares of the healthcare product maker’s stock, valued at approximately $274,000.

Other hedge funds have also recently made changes to their positions in the company. Hughes Financial Services LLC acquired a new stake in Abbott Laboratories during the 1st quarter worth about $27,000. Abound Financial LLC acquired a new stake in shares of Abbott Laboratories during the 1st quarter valued at about $28,000. Elequin Capital LP acquired a new stake in shares of Abbott Laboratories during the 1st quarter valued at about $30,000. JCIC Asset Management Inc. acquired a new stake in shares of Abbott Laboratories during the 1st quarter valued at about $32,000. Finally, Vision Financial Markets LLC acquired a new stake in shares of Abbott Laboratories during the 1st quarter valued at about $33,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Price Performance

Shares of ABT opened at $133.62 on Friday. Abbott Laboratories has a 1-year low of $110.86 and a 1-year high of $141.23. The stock has a market cap of $232.56 billion, a PE ratio of 16.74, a price-to-earnings-growth ratio of 2.53 and a beta of 0.69. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. The firm has a fifty day moving average price of $131.14 and a 200 day moving average price of $131.15.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.01 billion. During the same period in the previous year, the company earned $1.14 earnings per share. Abbott Laboratories’s quarterly revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, sell-side analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be issued a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio is presently 29.57%.

Insider Activity at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of the business’s stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ABT. Wells Fargo & Company dropped their target price on Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating on the stock in a research report on Friday, July 18th. Raymond James Financial decreased their target price on shares of Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating on the stock in a research note on Friday, July 18th. Leerink Partners initiated coverage on shares of Abbott Laboratories in a research report on Monday, June 16th. They set a “market perform” rating and a $143.00 price target on the stock. Jefferies Financial Group raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and lifted their price target for the company from $143.00 to $145.00 in a research report on Friday, July 18th. Finally, William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $145.22.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.